Developer docs
API playgroundTry for free, no card

Search company profiles

Ardena Group

Full company profile

uuid000912f

Namestring
Ardena Group
Legal namestring
Ardena Holding NV
Websiteurl
ardena.com
Company typeenum
Private
Founded yearint
2004
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersGhent, Belgium
HQ citystring
Ghent
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract pharmaceutical manufacturing, drug product development, nanomedicine formulation services, bioanalytical contract research, pharmaceutical CDMO services
Industry5 codes
PRIMARYHLAGAHAA
Small-Molecule API Process Development & Route Scouting
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGAHAI
Solid-State Chemistry & Preformulation (Polymorph/Crystallization)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAJ
Crystallization, Particle Engineering & Micronization Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code3 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Miscellaneous Chemical Products2890
Product category
Pharmaceutical CDMO and Bioanalytical CRO Services
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1CDMO Services - Drug Product Development
TypeProfessional Services
Description

Contract development and manufacturing services for drug products including formulation development, GMP manufacturing, and clinical trial supply

ardena.com
2CDMO Services - Drug Substance Manufacturing
TypeProfessional Services
Description

API manufacturing services including HPAPI, PROTACs, and specialized synthesis

ardena.com
3Bioanalytical CRO Services
TypeProfessional Services
Description

Contract research services for bioanalysis including biomarker analysis, immunogenicity testing, and clinical trial services

ardena.com
4Nanomedicine Development
TypeProfessional Services
Description

Specialized nanoparticle formulation and manufacturing services for precision medicine applications

ardena.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Ardena Group is an integrated Contract Development and Manufacturing Organization (CDMO) and bioanalytical Contract Research Organization (CRO) providing end-to-end pharmaceutical development services for complex molecules. Its offerings span four core service areas: Drug Product Development (oral solids, injectables, bioavailability enhancement via spray drying and hot melt extrusion), Nanomedicine Development (lipid, polymeric, and metal nanoparticles, ADCs/XDCs), Bioanalysis Services (biomarkers, immunogenicity, flow cytometry, qPCR, clinical trial services), and Drug Substance Services (PROTACs, molecular glues, solid state research, HPAPI manufacturing).

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Ardena is an integrated CDMO (Contract Development and Manufacturing Organisation) and bioanalytical CRO that specializes in complex drug development services. The company operates a unified platform combining four core service areas: Drug Product Development (covering oral solids, injectables, bioavailability enhancement via spray drying and hot melt extrusion, and clinical trial supply), Nanomedicine Development (lipid nanoparticles, polymeric nanoparticles, metal nanoparticles, ADCs/XDCs), Bioanalysis Services (biomarkers, immunogenicity, flow cytometry, qPCR), and Drug Substance Services (PROTACs, molecular glues, solid state research, HPAPI). The company has five manufacturing facilities across Europe and the US, offering end-to-end services from early development through GMP manufacturing.

Product and service6 records
1Drug Product Development
CategoryDrug Product Development
Description

End-to-end drug product development for small molecules with complex profiles, including poorly soluble compounds, highly potent APIs, controlled substances, and challenging physicochemical characteristics. Covers oral and injectable formulations, process chemistry, scale-up, and GMP manufacturing.

2Nanomedicine Development
CategoryNanomedicine Development
Description

Comprehensive nanomedicine platform covering lipid nanoparticles, polymeric nanoparticles, liposomes, nanosuspensions, and metal nanoparticles. Spans building block synthesis through GMP production and regulatory submission for nanoparticle-based therapeutics including ADCs and XDCs.

3Bioanalysis Services
CategoryBioanalytical CRO Services
Description

Full-range bioanalytical services from drug discovery research to phase IV clinical studies. Specializes in analyzing small molecules, proteins, vaccines, biomarkers, immunogenicity, flow cytometry, qPCR, and ADC/XDC PK panels.

4Drug Substance Services
CategoryDrug Substance Development
Description

Drug substance development covering PROTACs, glues and conjugates, solid state research including polymorph and salt screening, and high potency API (HPAPI) manufacturing capabilities with OEB 3-5 containment for cytotoxic oncology agents.

5Bioavailability Enhancement
CategoryDrug Product Development
Description

Technologies including spray drying and hot melt extrusion (HME) for amorphous solid dispersions (ASD) to enhance bioavailability of poorly soluble drugs.

6Clinical Trial Supply
CategoryClinical Trial Supply Services
Description

Clinical supply services including manufacturing, labeling, packaging, and distribution of clinical trial materials.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

Ardena divested its drug substance (API) site in Södertälje, Sweden to Nanologica AB. As part of the agreement, Ardena becomes a shareholder in Nanologica and CEO Jeremie Trochu joined Nanologica's Board of Directors.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-02-01
Description

Acquired Catalent's oral solids development and small-scale manufacturing facility in Somerset, New Jersey in February 2025. This strategic acquisition established Ardena's first US site and opened the door to North American bioanalytical services.

Strategic tierMinorTypeOthersAnnounced on2021-01-01
Description

Acquired Idifarma from Suanfarma as part of strategic expansion into Southern Europe. Idifarma was originally sold by Suanfarma to enable Ardena's growth in the Spanish market.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global CDMO offering drug product, drug substance, biologics, and clinical supply services across softgel, oral, sterile, and inhalation modalities. Direct competitor across Ardena's drug-product and HPAPI capabilities, and source of Ardena's recently acquired Somerset, NJ facility.

TypeDirect peer
Description

BC Partners-owned European CDMO providing solid dosage forms, sterile liquids, and semi-solids with HPAPI capability. Comparable in PE-backed scale, European footprint, and oral-solid / softgel service mix.

TypeDirect peer
Description

Permira-owned CDMO providing small-molecule API development, manufacturing, and drug-product services including HPAPI and controlled substances. Highly comparable in drug-substance focus, HPAPI specialization, and PE-backed mid-market position.

4Recipharm
TypeDirect peer
Description

EQT-owned European CDMO focused on oral solids, sterile injectables, APIs, and bioavailability enhancement. Closely comparable in service mix, customer base (small-to-mid pharma and biotech), and PE-backed mid-market positioning.

TypeBroad incumbent
Description

Global bioanalytical and pharmaceutical testing services provider with extensive central-lab and biomarker capabilities. Directly comparable to Ardena's Bioanalysis division across PK/PD, immunogenicity, and biomarker assays.

TypeBroad incumbent
Description

Swiss-listed global CDMO leader across small molecules, biologics, cell and gene therapies, and drug product. Comparable in drug-substance, HPAPI, and complex-molecule services, though significantly larger and broader than Ardena.

TypeBroad incumbent
Description

Patheon division of Thermo Fisher offers global drug product, API, and clinical trial services. Competes head-to-head on complex small molecules, sterile fill-finish, and bioavailability enhancement, with significantly greater scale and commercial reach.

TypeDirect peer
Description

PE-backed global CDMO specializing in clinical trial supply, commercial manufacturing, sterile injectables, and oral solid dose. Comparable in PE-owned mid-market CDMO positioning and integrated drug-product services.

TypeDirect peer
Description

Family-owned European CDMO specializing in aseptic fill-finish of sterile injectables and complex parenteral formulations. Comparable in high-complexity, regulated drug-product CDMO services and mid-to-large pharma customer base.

TypeDirect peer
Description

PE-backed bioanalytical CRO specializing in large-molecule PK, immunogenicity, and biomarker services for biologics and gene therapies. Closely comparable to Ardena's Bioanalysis division in customer base, services, and PE-owned mid-market positioning.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries5 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A5 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ardena Group

Pharmaceutical CDMO and Bioanalytical CRO Servicesardena.com

Ardena Group firmographics

Firmographics
Name
Ardena Group
Legal name
Ardena Holding NV
Website
https://ardena.com
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
501–1,000 employees
Ownership category
akta.pro rank

Ardena Group industry classification

Industry
Product category
Pharmaceutical CDMO and Bioanalytical CRO Services
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834), Miscellaneous Chemical Products (2890)
akta.pro industry
PRIMARYHLAGAHAA
Small-Molecule API Process Development & Route Scouting
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGAHAI
Solid-State Chemistry & Preformulation (Polymorph/Crystallization)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAJ
Crystallization, Particle Engineering & Micronization Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Contract pharmaceutical manufacturing
  • Drug product development
  • Nanomedicine formulation services
  • Bioanalytical contract research
  • Pharmaceutical CDMO services

Where Ardena Group is headquartered

Location

Headquarters

HQ city
Ghent
HQ country
Belgium
HQ region
Europe

Offices5 records

Markets served

Ardena Group business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. CDMO Services - Drug Product Development: Contract development and manufacturing services for drug products including formulation development, GMP manufacturing, and clinical trial supply
  2. CDMO Services - Drug Substance Manufacturing: API manufacturing services including HPAPI, PROTACs, and specialized synthesis
  3. Bioanalytical CRO Services: Contract research services for bioanalysis including biomarker analysis, immunogenicity testing, and clinical trial services
  4. Nanomedicine Development: Specialized nanoparticle formulation and manufacturing services for precision medicine applications

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Ardena Group product offering

Product offering

Core offering

Ardena Group is an integrated Contract Development and Manufacturing Organization (CDMO) and bioanalytical Contract Research Organization (CRO) providing end-to-end pharmaceutical development services for complex molecules. Its offerings span four core service areas: Drug Product Development (oral solids, injectables, bioavailability enhancement via spray drying and hot melt extrusion), Nanomedicine Development (lipid, polymeric, and metal nanoparticles, ADCs/XDCs), Bioanalysis Services (biomarkers, immunogenicity, flow cytometry, qPCR, clinical trial services), and Drug Substance Services (PROTACs, molecular glues, solid state research, HPAPI manufacturing).

Product overview

Ardena is an integrated CDMO (Contract Development and Manufacturing Organisation) and bioanalytical CRO that specializes in complex drug development services. The company operates a unified platform combining four core service areas: Drug Product Development (covering oral solids, injectables, bioavailability enhancement via spray drying and hot melt extrusion, and clinical trial supply), Nanomedicine Development (lipid nanoparticles, polymeric nanoparticles, metal nanoparticles, ADCs/XDCs), Bioanalysis Services (biomarkers, immunogenicity, flow cytometry, qPCR), and Drug Substance Services (PROTACs, molecular glues, solid state research, HPAPI). The company has five manufacturing facilities across Europe and the US, offering end-to-end services from early development through GMP manufacturing.

Differentiator

Problem solved

Functional benefit

Products and services

  • Drug Product Development End-to-end drug product development for small molecules with complex profiles, including poorly soluble compounds, highly potent APIs, controlled substances, and challenging physicochemical characteristics. Covers oral and injectable formulations, process chemistry, scale-up, and GMP manufacturing.
  • Nanomedicine Development Comprehensive nanomedicine platform covering lipid nanoparticles, polymeric nanoparticles, liposomes, nanosuspensions, and metal nanoparticles. Spans building block synthesis through GMP production and regulatory submission for nanoparticle-based therapeutics including ADCs and XDCs.
  • Bioanalysis Services Full-range bioanalytical services from drug discovery research to phase IV clinical studies. Specializes in analyzing small molecules, proteins, vaccines, biomarkers, immunogenicity, flow cytometry, qPCR, and ADC/XDC PK panels.
  • Drug Substance Services Drug substance development covering PROTACs, glues and conjugates, solid state research including polymorph and salt screening, and high potency API (HPAPI) manufacturing capabilities with OEB 3-5 containment for cytotoxic oncology agents.
  • Bioavailability Enhancement Technologies including spray drying and hot melt extrusion (HME) for amorphous solid dispersions (ASD) to enhance bioavailability of poorly soluble drugs.
  • Clinical Trial Supply Clinical supply services including manufacturing, labeling, packaging, and distribution of clinical trial materials.

Companies that use Ardena Group

Customer profile

Segments2 records

Ideal customer profiles2 records

Ardena Group technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Ardena Group partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered minor and core.

  • Nanologica ABminorStrategic or Co-development Partner · 1 January 2026Ardena divested its drug substance (API) site in Södertälje, Sweden to Nanologica AB. As part of the agreement, Ardena becomes a shareholder in Nanologica and CEO Jeremie Trochu joined Nanologica's Board of Directors.
  • CatalentcoreStrategic or Co-development Partner · 1 February 2025Acquired Catalent's oral solids development and small-scale manufacturing facility in Somerset, New Jersey in February 2025. This strategic acquisition established Ardena's first US site and opened the door to North American bioanalytical services.
  • SuanfarmaminorOthers · 1 January 2021Acquired Idifarma from Suanfarma as part of strategic expansion into Southern Europe. Idifarma was originally sold by Suanfarma to enable Ardena's growth in the Spanish market.

Scale indicators6 records

Recent moves8 records

Expansion highlights6 records

Ardena Group competitors and assessment

Company assessment

Broad incumbents

  • Catalent: Global CDMO offering drug product, drug substance, biologics, and clinical supply services across softgel, oral, sterile, and inhalation modalities. Direct competitor across Ardena's drug-product and HPAPI capabilities, and source of Ardena's recently acquired Somerset, NJ facility.
  • Eurofins Scientific: Global bioanalytical and pharmaceutical testing services provider with extensive central-lab and biomarker capabilities. Directly comparable to Ardena's Bioanalysis division across PK/PD, immunogenicity, and biomarker assays.
  • Lonza Group: Swiss-listed global CDMO leader across small molecules, biologics, cell and gene therapies, and drug product. Comparable in drug-substance, HPAPI, and complex-molecule services, though significantly larger and broader than Ardena.
  • Thermo Fisher Scientific (Patheon): Patheon division of Thermo Fisher offers global drug product, API, and clinical trial services. Competes head-to-head on complex small molecules, sterile fill-finish, and bioavailability enhancement, with significantly greater scale and commercial reach.

Direct peers

  • Aenova Group: BC Partners-owned European CDMO providing solid dosage forms, sterile liquids, and semi-solids with HPAPI capability. Comparable in PE-backed scale, European footprint, and oral-solid / softgel service mix.
  • Cambrex: Permira-owned CDMO providing small-molecule API development, manufacturing, and drug-product services including HPAPI and controlled substances. Highly comparable in drug-substance focus, HPAPI specialization, and PE-backed mid-market position.
  • Recipharm: EQT-owned European CDMO focused on oral solids, sterile injectables, APIs, and bioavailability enhancement. Closely comparable in service mix, customer base (small-to-mid pharma and biotech), and PE-backed mid-market positioning.
  • PCI Pharma Services: PE-backed global CDMO specializing in clinical trial supply, commercial manufacturing, sterile injectables, and oral solid dose. Comparable in PE-owned mid-market CDMO positioning and integrated drug-product services.
  • Vetter Pharma: Family-owned European CDMO specializing in aseptic fill-finish of sterile injectables and complex parenteral formulations. Comparable in high-complexity, regulated drug-product CDMO services and mid-to-large pharma customer base.
  • BioAgilytix Labs: PE-backed bioanalytical CRO specializing in large-molecule PK, immunogenicity, and biomarker services for biologics and gene therapies. Closely comparable to Ardena's Bioanalysis division in customer base, services, and PE-owned mid-market positioning.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Ardena Group social profiles

Digital presence

Ardena Group financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ardena Group leadership team

Management profile

Number of profiles

Profiles9 records

Ardena Group subsidiaries and ownership

Company hierarchy

Subsidiaries5 records

Ardena Group funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ardena Group M&A and investment

M&A and investment

M&A5 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ardena Group

What does Ardena Group do?

Ardena Group is an integrated Contract Development and Manufacturing Organization (CDMO) and bioanalytical Contract Research Organization (CRO) providing end-to-end pharmaceutical development services for complex molecules. Its offerings span four core service areas: Drug Product Development (oral solids, injectables, bioavailability enhancement via spray drying and hot melt extrusion), Nanomedicine Development (lipid, polymeric, and metal nanoparticles, ADCs/XDCs), Bioanalysis Services (biomarkers, immunogenicity, flow cytometry, qPCR, clinical trial services), and Drug Substance Services (PROTACs, molecular glues, solid state research, HPAPI manufacturing).

Is Ardena Group a public or private company?

Ardena Group is a private company. It is classified as private equity controlled and is currently operating.

When was Ardena Group founded?

Ardena Group was founded in 2004. It employs 501 to 1,000 people.

Where is Ardena Group based?

Ardena Group is headquartered in Ghent, Belgium, in the Europe region.

How does Ardena Group make money?

Four revenue lines are on record. CDMO Services - Drug Product Development is the primary driver. The others are CDMO Services - Drug Substance Manufacturing, bioanalytical CRO Services and nanomedicine Development.

Who are Ardena Group's main competitors?

Broad incumbents on record are Catalent, Eurofins Scientific, Lonza Group and Thermo Fisher Scientific (Patheon). Direct peers are Aenova Group, Cambrex, Recipharm, PCI Pharma Services, Vetter Pharma and BioAgilytix Labs.

Does Ardena Group have an API?

No public API is recorded for Ardena Group.

What industry is Ardena Group in?

Ardena Group's product category is Pharmaceutical CDMO and Bioanalytical CRO Services. Its primary akta.pro industry code is HLAGAHAA, Small-Molecule API Process Development & Route Scouting, with a secondary code of HLAGAAAD, Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceArdena appoints Ariane de Ganck as Chief Scientific OfficerArdena appointed Ariane de Ganck as Chief Scientific Officer, effective June 1, 2026. She previously led the Drug Product division since 2022 and served as Chief Commercial Officer. The appointment coincides with Ardena's refreshed brand identity and tagline 'We know development™'.GlobeNewswireArdena Opens New Bioanalytical Laboratory in Somerset, New JerseyArdena opened a new GLP bioanalytical laboratory in Somerset, New Jersey, on April 15, 2026, supporting client studies. The 2,500+ sqft facility includes LC-MS/MS and immunochemistry platforms for preclinical and clinical analysis. Ardena plans to expand the site with additional platforms and teams.GlobeNewswireArdena Appoints Paul Edwards as Chief People OfficerArdena appointed Paul Edwards as Chief People Officer, leading global people strategy and organizational capability. He brings over 30 years of HR leadership, including 16 years at Catalent Pharma Solutions. His mandate includes simplifying structures and developing talent to support international growth.GlobeNewswireArdena strengthens executive leadership with appointments of Chief Quality Officer and Chief Information OfficerArdena, a specialist pharmaceutical CDMO and bioanalytical CRO headquartered in Ghent, Belgium, has appointed Dipesh Patel as Chief Quality Officer and Peter Rose as Chief Information Officer. Dipesh Patel brings over 25 years of pharmaceutical industry experience, including senior roles at Accord Healthcare and Catalent, and is a certified EU Qualified Person; Peter Rose has over 25 years of IT leadership experience, most recently at Diversey and a decade at Catalent, where he oversaw global IT systems. The appointments are intended to strengthen Ardena's executive leadership with a focus on quality, compliance, and digital integration to support the company's global growth in precision medicines.Towards HealthcareMedical Device CMO and CDMO Market Growth with Forecast 2025 to 2034The global medical device CMO and CDMO market is experiencing significant growth driven by the increasing outsourcing of manufacturing and development services to enhance efficiency and reduce costs. North America currently dominates the sector with a substantial revenue share, while Asia-Pacific is projected to grow at the fastest compound annual growth rate during the forecast period from 2025 to 2034. Key industry developments include strategic acquisitions and facility expansions by major players such as Jabil, Ardena, and Syngene International to expand production capacities and service offerings.YahooArdena Completes Acquisition of Advanced Drug Product Manufacturing Facility from Catalent and Expands Bioanalytical Services in North AmericaArdena completed the acquisition of Catalent's drug product manufacturing facility in Somerset, New Jersey, and opened a new bioanalytical lab there. The facility has over 50,000 sq ft of cGMP space and 200+ staff, with the lab expected operational by Q3 2025.ArdenaArdena Completes Acquisition of Advanced Drug Product Manufacturing Facility from Catalent and Expands Bioanalytical Services in North AmericaArdena has completed the acquisition of an advanced drug product manufacturing facility from Catalent and is expanding its bioanalytical services in North America. This transaction marks a strategic expansion for Ardena's operational capabilities in the region.Bioanalysis-ZoneArdena meets the growing demand for bioanalytical testing servicesArdena is expanding its bioanalytical services in the Netherlands by investing in a new state-of-the-art lab in Oss and upgrading its facility in Assen to meet rising global demand for drug development support. The new Oss laboratory, scheduled to open by Q1 2025, will feature advanced analytical testing technologies for both small and large molecules, while the Assen site will enhance capabilities for therapeutic modalities ranging from discovery to late-stage clinical phases.YahooCatalent to sell New Jersey drug facility to ArdenaArdena, a Belgium-based contract manufacturer, will acquire Catalent's oral drug products facility in Somerset, New Jersey, with 200 employees. The deal is expected to close in early 2025, subject to customary conditions, and will strengthen Ardena's downstream manufacturing capabilities. The transaction amount was not disclosed.